Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.44 |
| ▸ | GYS1 | P13807 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | VHL | P40337 | 2/20 | 0.41 |
| ▸ | ELOC | Q15369 | 1/20 | 0.41 |
| ▸ | ELOB | Q15370 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16277201 | 0.89 | VHL (0.45) | FKBP1AACEALDH1A1HPGDVHL | |
| SCHEMBL15126024 | 0.85 | VHL (0.59) | VHLELOCELOB | |
| SCHEMBL21697218 | 0.84 | VHL (0.56) | ALDH1A1VHLELOCELOB | |
| SCHEMBL21697315 | 0.83 | CPT2 (0.52) | ALDH1A1VHLELOCELOB | |
| SCHEMBL21696618 | 0.80 | VHL (0.53) | ALDH1A1SMN1; SMN2VHL | |
| SCHEMBL15126220 | 0.79 | VHL (0.53) | ACEALDH1A1HPGDVHL | |
| SCHEMBL15126160 | 0.79 | VHL (0.58) | ALDH1A1VHLELOCELOB | |
| SCHEMBL15126148 | 0.79 | VHL (0.63) | FKBP1AHPGDVHLELOCELOB | |
| SCHEMBL6787737 | 0.78 | FKBP1A (0.62) | FKBP1AACE | |
| SCHEMBL6787731 | 0.78 | FKBP1A (0.62) | FKBP1AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | FKBP1A 589/4885ACE 1300/4885MMEL1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.